Edition:
India

Redhill Biopharma Ltd (RDHL.OQ)

RDHL.OQ on NASDAQ Stock Exchange Capital Market

6.22USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$6.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
44,567
52-wk High
$11.24
52-wk Low
$4.30

Chart for

About

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointes... (more)

Overall

No Ratios Available.

Financials

BRIEF-Redhill Biopharma Q4 Basic Loss Per Ordinary Share $0.05

* CASH BALANCE AS OF DECEMBER 31, 2017 WAS $46.2 MILLION, A DECREASE OF $20 MILLION, COMPARED TO $66.2 MILLION AS OF DECEMBER 31, 2016 Source text for Eikon: Further company coverage:

22 Feb 2018

BRIEF-Redhill Biopharma Announces Final Results From Phase II Study With Bekinda For IBS-D

* REDHILL BIOPHARMA ANNOUNCES FINAL RESULTS FROM PHASE II STUDY WITH BEKINDA® FOR IBS-D

16 Jan 2018

BRIEF-Redhill Biopharma Initiates Phase IIa Study With Abc294640(Yeliva) For Cholangiocarcinoma

* REDHILL BIOPHARMA ANNOUNCES INITIATION OF PHASE IIA STUDY WITH ABC294640 (YELIVA®) FOR CHOLANGIOCARCINOMA AT MAYO CLINIC AND MD ANDERSON Source text for Eikon: Further company coverage:

22 Dec 2017

BRIEF-Redhill Biopharma provides 2017 year-end business update

* REDHILL BIOPHARMA LTD - ‍COST REDUCTION PLAN IS IN PLACE TO GRADUALLY REDUCE AVERAGE QUARTERLY CASH BURN RATE IN 2018 TO APPROXIMATELY $8.5 MILLION​

05 Dec 2017

BRIEF-Redhill biopharma Q3 ‍loss per ordinary share US$0.09

* Redhill Biopharma reports 2017 third quarter financial results

13 Nov 2017

BRIEF-Redhill Biopharma says last patient enrolled in Phase III study with RHB-104 for Crohn’s disease

* Redhill Biopharma announces last patient enrolled in the Phase III study with RHB-104 for Crohn's disease

09 Nov 2017

BRIEF-RedHill Biopharma prices public offering of its American Depositary Shares

* RedHill Biopharma prices public offering of its American Depositary Shares

08 Nov 2017

BRIEF-Redhill Biopharma announces proposed public offering of its American Depositary Shares

* Redhill Biopharma announces proposed public offering of its american depositary shares Source text for Eikon: Further company coverage:

08 Nov 2017

BRIEF-IntelGenx and Redhill Biopharma resubmit Rizaport NDA to FDA

* Intelgenx and Redhill Biopharma resubmit Rizaport new drug application to the FDA

01 Nov 2017

BRIEF-Redhill Biopharma and Intelgenx submit new drug application to FDA for Rizaport® for migraines

* Redhill Biopharma and Intelgenx submit new drug application to FDA for Rizaport® for migraines

01 Nov 2017

Earnings vs. Estimates